WCLC 2018: Comprehensive Genomic Profiling Aids in Identifying Personalized Therapeutic Options

Key Points

  • A total of 263 genomic alterations were identified in this patient population.
  • Of these patients, 13% were referred to clinical trials, and 26% of their genetic profiling results spurred a change in therapy.
  • Among those diagnosed with lung cancer, 6% were referred to clinical trials, and 34% had a change in therapy.

Study findings demonstrated that comprehensive genetic profiling is a useful tool in directing patient care, identifying targeted therapies, and enrolling patients in clinical trials. Kimberly Rohan, MS, APN, AOCNP®, a nurse practitioner at the Edward Cancer Center in Naperville, Illinois, presented these results at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (Abstract OA04.03).

Analysis of Comprehensive Genetic Profiling

A retrospective analysis was performed on the results of comprehensive genetic profiling collected from 46 patients with a cancer diagnosis utilizing Foundation Medicine’s FoundationOne technology over a 3-year period. Each case was reviewed for the number of genomic alterations identified, the treatment associated with potential for clinical trial benefit, therapies associated with lack of response, and clinical decisions made due to the genomic profiling findings.

A total of 263 genomic alterations were identified in this patient population. Of these patients, 13% were referred to clinical trials, and 26% of their genetic profiling results spurred a change in therapy. Among those diagnosed with lung cancer, 6% were referred to clinical trials, and 34% had a change in therapy.

“We’re thrilled to have achieved our goal, analyzing how information obtained in genomic profiling can impact or change patient care,” said Ms. Rohan. “Our findings, ranging from 6% to 13% of patients referred to clinical trials, exceed the national clinical trial enrollment and highlight a substantial opportunity for patients undergoing cancer treatment.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.